Developer & Partner: Developed by the CSIR–Institute of Genomics and Integrative Biology (CSIR-IGIB) in partnership with the Serum Institute of India (SIIPL) for tech transfer, scaling, and manufacturing. Naming: Dedicated to tribal freedom fighter Bhagwan Birsa Munda on his 150th birth anniversary. Target Population: Focuses on treating severe sickle cell anemia, which heavily affects tribal communities across central and eastern India. Affordability: Aimed at slashing the cost of gene therapy drastically down to an estimated ₹50 lakh compared to international alternatives that cost ₹20–25 crore. Timeline: Phase-I clinical trials are expected to commence around 2027 as part of India’s National Sickle Cell Anemia Elimination Mission by 2047.